Manufacturing, Cell-Line Selection

Dyadic International Selected for COVID-19 Vaccine Candidate Development

June 11, 2020

The candidates will be used by the Vaccine Research Center, part of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.

Catalent Partners with Spicona for COVID-19 Vaccine Development

June 10, 2020

Catalent will use its GPEx cell line development technology to create a cell line expressing the recombinant VLP at its Madison, WI facility.

Biopharmaceutical Manufacturing and the Power of Synthetic Biology

May 01, 2020

BioPharm International

Synthetic biology has advanced the scope and scale with which biologically derived therapeutics can be developed.

Solentim, ATUM Parnter on Cell Line Development

April 30, 2020

Solentim and ATUM will bundle together the Leap-In Transposase platform with the VIPS single cell cloning instrument for cell line development.

Immutep, Batavia Biosciences Generate High-Yielding LAG-3 Cell Line

April 16, 2020

This milestone achievement will allow the companies to move forward with developing a GMP-compliant manufacturing process for clinical testing.

The Future of Raw Material Sources for mAbs

March 02, 2020

BioPharm International

The future of raw material sourcing for mAb production may lay in the sustainability of the source and the added benefits of newer technologies.

Abcam Purchases ASC’s Gene Editing Platform and Oncology Product Portfolio

January 31, 2020

Abcam has purchased Applied StemCell’s (ASC’s) gene editing platform and oncology product portfolio, adding comprehensive cell editing capabilities and engine to support expansion of existing “off-the-shelf” cell lines.

Horizon Discovery Grants Access to Base Editing Technology

January 16, 2020

The next-generation gene editing system can be applied to the development of novel cell and gene therapies.

ProBioGen, Lava Therapeutics Close Development and Manufacturing Agreement

January 15, 2020

ProBioGen and Lava Therapeutics have closed the cell line development and manufacturing agreement for Lava’s novel bispecific antibody lead candidate.

Charles River Partners with Bit Bio for Human Cell Suite Expansion

December 12, 2019

Through the collaboration, Charles River plans to expand its suite of authentic human cells by utilizing Bit Bio’s target discovery, validation, and screening services to further the development of therapies with a higher chance of success in patients.